Journal
CARDIOVASCULAR DIABETOLOGY
Volume 21, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12933-022-01516-6
Keywords
Type 2 diabetes mellitus; Cardiovascular diseases; Hyperlipidemia; Hypertension; Therapy principle; Antidiabetic therapy
Funding
- Lanzhou Chengguan District Science and Technology Plan Project [2021-9-19]
- Construction Program of Gansu Provincial Clinical Medical Research Center for Endocrine Diseases [20JR10FA667]
- Gansu Provincial Natural Science Foundation [20JR10RA681]
- Special Funds of Science and Technology Development of the Chinese Central Government to Guide Local in 2020 [1004TCYA032]
- Hospital Fund of the First Hospital of Lanzhou University [ldyyyn2020-93]
Ask authors/readers for more resources
This review mainly discusses the important issues in choosing antidiabetic agents and lipid, blood pressure, and antiplatelet treatments for patients with T2DM, considering their cardiovascular status. Additionally, changes in therapy principles for CVDs in T2DM are also addressed.
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
